• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
September 30, 2022 02:03 PM EDTUpdated 02:48 PM
Coronavirus
Law

In­dus­try groups call to block WTO IP waiv­er ex­pan­sion to Covid-19 ther­a­peu­tics

Zachary Brennan

Senior Editor

The WTO’s TRIPS Coun­cil in mid-Oc­to­ber is ex­pect­ed to de­bate whether to ex­tend the IP waiv­er for Covid-19 vac­cines to ther­a­peu­tics and di­ag­nos­tics too. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • Gener­ic mifepri­s­tone mak­er los­es bid to over­turn West Vir­ginia an­ti-abor­tion law July 15, 2025
  • Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids July 15, 2025
  • Judge re­jects Ab­b­Vie’s fight against Mis­souri 340B con­tract phar­ma­cy law July 14, 2025
TRENDING NOW

Sarep­ta adds black box warn­ing to its Duchenne treat­ment, cuts 500 work­ers

RFK reshuf­fles top HHS lead­er­ship, re­plac­ing his chief of staff and an­oth­er top aide

Bay­er ex­tends CEO Bill An­der­son­'s con­tract through March 2029

FDA drugs cen­ter sees sharp rise in staff de­par­tures since Jan­u­ary

PureTech CEO leaves just one week af­ter long­time chair steps down

As­traZeneca says amy­loi­do­sis drug fails Phase 3 tri­als, but claims po­ten­tial in undis­closed sub­group

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times